Transforming frowth factor-β is upregulated in tumors and changes from tumor-suppressive to tumor-promoting activity. PM8001 is a PD-L1 inhibitor that neutralizes the activity of TGFβ simultaneously. By enriching TGFβ neutralization into the tumor microenvironment, potential off-target effects of TGFβ neutralization may be limited whilst providing synergistic blockade.